Miami, Florida – Over 130 batches of blood pressure medication have been recalled due to concerns that the pill capsules may not dissolve properly when taken by patients. Glenmark Pharmaceuticals recalls 114 batches of 750 mg Potassium Chloride contained in bottles with 100 and 500 pills, with the specific batch numbers and expiration dates detailed in a document circulated by the FDA. American Health Packaging also issued a voluntary recall of 21 batches of the same medicine on behalf of BluePoint Laboratories.
The failure of the potassium chloride extended-release capsules to dissolve properly could potentially lead to high potassium levels in the blood, known as hyperkalemia. This condition can result in irregular heartbeats that may lead to cardiac arrest, highlighting the serious health risks associated with the defective medication.
Patients who rely on this specific blood pressure medication to manage their condition and prevent heart or kidney failure are particularly vulnerable, as the effectiveness of the pills has been compromised. Those who have been prescribed the recalled batches are at risk of experiencing symptoms of hyperkalemia, such as cardiac arrhythmias, severe muscle weakness, and potentially death.
Despite the recall, Glenmark Pharmaceuticals has not yet received any reports of hyperkalemia or adverse events related to the affected medication. However, as a precautionary measure, the company has advised wholesale, distributor, and retail outlets nationwide to remove the products from shelves immediately. Patients who have been taking this medication are encouraged to consult with their healthcare provider before discontinuing use.
In light of the potential health risks posed by the recalled medication, individuals are urged to be vigilant for symptoms of hyperkalemia and to seek medical attention promptly if any signs appear. The FDA is reminding the public to report any adverse events related to the medication through its MedWatch Adverse Event Reporting program, either online, by mail, or via fax. This serves as a crucial step in ensuring the safety and well-being of patients who may have been exposed to the defective blood pressure medication.